The US Food and Drug Administration’s imminent action on Biogen Pharma and Eisai Co., Ltd.’s Alzheimer’s drug aducanumab is bound to be controversial, regardless of whether the agency approves the biologics license application or issues a complete response letter.
Questions about the robustness of the efficacy data, internal FDA disagreement on the application’s merits, harsh advisory committee criticism of...






